Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: A population-based study

Journal of Clinical Oncology

Volumn 32, Issue 9, 2014, Pages 927-934

  Vaz Luis, Ines ^a,d   Keating, Nancy L ^b,c   Lin, Nancy U ^a   Lii, Huichuan ^c   Winer, Eric P ^a   Freedman, Rachel A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CARDIOMYOPATHY; CARDIOTOXICITY; COMORBIDITY; FEMALE; HEART FAILURE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICARE; PARTIAL MASTECTOMY; PRIORITY JOURNAL; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER REGISTRY; MULTIVARIATE ANALYSIS; PATHOLOGY; STATISTICAL MODEL; UNITED STATES;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LOGISTIC MODELS; MEDICARE; MULTIVARIATE ANALYSIS; RECEPTOR, ERBB-2; SEER PROGRAM; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84899644277     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.1261     Document Type: Article

References (22)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987 (Pubitemid 17231334)
2. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989 (Pubitemid 19147683)
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
4. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
5. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
6. Untch M, Gelber RD, Jackisch C, et al: Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 19:1090-1096, 2008 (Pubitemid 351796334)
7. Moja L, Tagliabue L, Balduzzi S, et al: Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 4:CD006243, 2012
8. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006 (Pubitemid 43290919)
9. Pivot X, Romieu G, Bonnefoi H, et al: PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. Cancer Res 72, 2012 (suppl 24; abstr S5-3)
10. Romond EH, Jeong JH, Rastogi P, et al: Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792-3799, 2012
11. Freedman RA, Hughes ME, Ottesen RA, et al: Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer 119:839-846, 2013
12. Chen J, Long JB, Hurria A, et al: Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60:2504-2512, 2012
13. Potosky AL, Warren JL, Riedel ER, et al: Measuring complications of cancer treatment using the SEER-Medicare data. Med Care 40:IV-62-8, 2002
14. Warren JL, Klabunde CN, Schrag D, et al: Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 40:IV-3-18, 2002
15. Klabunde CN, Potosky AL, Legler JM, et al: Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258-1267, 2000 (Pubitemid 32007842)
16. Charlson M, Szatrowski TP, Peterson J, et al: Validation of a combined comorbidity index. J Clin Epidemiol 47:1245-1251, 1994 (Pubitemid 24361532)
17. Bueno H, Ross JS, Wang Y, et al: Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA 303:2141-2147, 2010
18. Hurria A, Wong FL, Villaluna D, et al: Role of age and health in treatment recommendations for older adults with breast cancer: The perspective of oncologists and primary care providers. J Clin Oncol 26:5386-5392, 2008
19. Hurria A, Wong FL, Pal S, et al: Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: A survey of oncologists. Oncologist 14:883-890, 2009
20. Perez EA, Romond EH, Suman VJ, et al: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373, 2011
21. Bowles EJ, Wellman R, Feigelson HS, et al: Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 104:1293-1305, 2012
22. Lund JL, Stürmer T, Harlan LC, et al: Identifying specific chemotherapeutic agents in Medicare data: A validation study. Med Care 51:e27-e34, 2013